Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 63 | ECE2019 | Next issue

21st European Congress of Endocrinology

Lyon, France
18 May 2019 - 21 May 2019

Card image cap
18-21 May 2019, Lyon, France

Guided Posters


ea0063gp153 | Cushing's | ECE2019

Evaluation of the corticotrophin-releasing-hormone test and the high dose dexamethasone suppression test in ACTH dependent Cushing’s syndrome: a 25-year prospective cohort study

Muller Dion R.P. , Gent-Houben Moniek C.F. , van Vessem-Timmermans Martine , Linthorst Gabor E. , Serlie Mireille J. , Siegelaar Sarah E. , Soeters Maarten R. , Hillebrand Jacquelien J. , Heijboer Annemieke C. , Fliers Eric , Bisschop Peter H. , Jan Stenvers Dirk

Introduction: In patients with ACTH-dependent hypercortisolism, the corticotropin-releasing-hormone (CRH) test and the high dose dexamethasone suppression test (HDDST) can be used to differentiate between pituitary ACTH production (Cushing’s disease) and ectopic ACTH production. The rationale is that a pituitary adenoma will show some response to CRH and ACTH whereas an ectopic source is less responsive to ACTH and CRH. However, there is discussion about the clinical util...

ea0063gp154 | Cushing's | ECE2019

Pathway enrichment analysis in functioning and silent corticotroph pituitary adenomas reveals mechanisms to explain their distinct clinical behaviour

Olarescu Nicoleta Cristina , Normann Kjersti Ringvoll , Sundaram Arvind YM , Oystese Kristin Astrid Berland , Eieland Alexander , Lekva Tove , Bollerslev Jens

Background: Functioning (FCA) and silent corticotroph (SCA) pituitary adenomas act differently from a clinical perspective, despite both subtypes showing positive ACTH staining by immunohistochemistry. They are challenging to treat, the former due to functional ACTH production and consequently hypercortisolemia leading to Cushing disease, whereas the latter due to invasive and recurrent behaviour. Moreover, the molecular mechanisms behind their distinct behaviour are not clear...

ea0063gp155 | Cushing's | ECE2019

Endocrine immune-related adverse events following immune checkpoint inhibitors in patients with advanced melanoma: single-center retrospective analysis

Kassi Eva , Angelousi Anna , Asonitis Nikos , Petychaki Foteini , Diamantopoulos Panayiotis , Anastasopoulou Amalia , Benopoulou Olga , Gogas Helen

Introduction: Immune-check point inhibitors (ICPis) has been shown to significantly improve survival in patients with advanced melanoma. Immune-related endocrinopathies (irEs) and in particular hypophysitis and thyroid dysfunction have been well described with an incidence varying from 9–17% and 3.8–13.2% respectively.Methods: This is a retrospective analysis of irEs in 325 (190 men) patients with melanoma receiving ICPis (PD-1/PDL-1 or CTLA-4 ...

ea0063gp156 | Cushing's | ECE2019

Correlation between responsiveness to CRH stimulation test in Cushing’s disease patients and USP8 mutational status

Albani Adriana , Perez-Rivas Luis , Buchfelder Michael , Honegger Jurgen , Stalla Gunter , Zopp Stefanie , Reincke Martin , Theodoropoulou Marily

Corticotrophin-releasing hormone (CRH) stimulation test is used in the differential diagnosis of Cushing’s syndrome. Cushing’s disease tumours carry somatic driver activating mutations in the ubiquitin-specific-protease 8 (USP8) gene in almost half of the cases. The aim of the present study was to examine whether the USP8 mutational status in Cushing’s disease tumours influences the response to the CRH stimulation test. We did a monocentric, re...

ea0063gp157 | Cushing's | ECE2019

DNA Methylation and fMRI responses in patients with Cushing’s syndrome in remission – suggestions of a functional link between hypercortisolism and neurocognitive dysfunction

Glad Camilla , Andersson-Assarsson Johanna , Stomby Andreas , Dahlqvist Per , Nyberg Lars , Bergthorsdottir Ragnhildur , Johannsson Gudmundur , Ragnarsson Oskar

Introduction: Compared with healthy controls, women with Cushing’s syndrome (CS) in long-term remission have reduced functional brain responses during episodic and working memory testing and decreased overall levels of DNA methylation in blood cells. Here, we sought to test the hypothesis that functional brain responses in the prefrontal cortex and hippocampus are related to epigenetic changes in subjects with CS in long-term remission.Methods: In t...

ea0063gp158 | Cushing's | ECE2019

Cortisol and cortisone assays in hair by mass spectrometry for the diagnosis of Cushing’s syndrome

Brossaud Julie , De Angeli Delia , Corcuff Jean-Benoit , Charret Lea , Tabarin Antoine

Background: According to the Endocrine Society’s guidelines, the screening and diagnosis of Cushing’s syndrome (CS) are based on the results of the overnight dexamethasone suppression test (DST), midnight salivary cortisol and 24-hour urinary free cortisol (UFC) measurements. These 3 tests reflect cortisol levels at the time of sampling without providing retrospective information. Hair cortisol concentration is a non-invasive way to measure cortisol exposure over lon...

ea0063gp159 | Cushing's | ECE2019

Skeletal muscle fatty infiltration in the thigh, as assessed by MRI T2-weighted and 3-point Dixon sequences, is associated with poor performance on muscle function testing in patients with Cushing’s syndrome in remission

Martel Luciana , Alonso Alicia , Bascunana Helena , Manera Jordi Diaz , Llauger Jaume , Nunez-Peralta Claudia , Biagetti Betina , Montesinos Paula , Webb Susan , Valassi Elena

Background: Muscle weakness may persist in patients with Cushing’s syndrome (CS) long-term after resolution of hypercortisolism, but mechanisms determining this sustained impairment are not known. We hypothesized that alteration of muscle structure, due to fatty infiltration, is associated with muscle dysfunctions in these patients.Patients & methods: Twenty-six CS women [mean(±S.D.) age 49±12 years; mean(±S....

ea0063gp160 | Cushing's | ECE2019

Brain 18F-fluorodeoxyglucose PET/CT in localization of MRI-negative ACTH-producing pituitary adenomas

Tsoy Uliana , Ryzhkova Daria , Cherebillo Vladislav , Ryzhkov Anton , Kuritsyna Natalia , Belousova Lidia , Dalmatova Anna , Grineva Elena

Background: Detection of MRI-negative ACTH-producing pituitary adenomas is a challenge in the management of patients with Cushing’s disease. There are some data on the possibility of pituitary adenomas to accumulate 18F-fluorodeoxyglucose (18F-FDG) during the 18F-FDG positron emission tomography and computer tomography (18F-FDG PET/CT).Aim: To study the potential of brain 18F-fluorodeoxyglucose PET/CT for localization of MRI-negative ACTH-producing ...

ea0063gp161 | Cushing's | ECE2019

Ubiquitin-specific protease 8 (USP8) potentiates glucocorticoid receptor activity in corticotroph tumour cells

Perez-Rivas Luis , Ciato Denis , Colon-Bolea Paula , Reincke Martin , Theodoropoulou Marily

Cushing’s disease tumours bear activating mutations in the ubiquitin-specific-protease 8 gene (USP8) gene in 40-60% of cases. We have previously observed that patients with USP8 mutant tumours have smaller tumour size and show a better response to high dose (8mg) dexamethasone stimulation test compared to those with wild type USP8 (1). The aim of this study was to define the role of USP8 on glucocorticoid receptor (GR) in corticotroph tumour cells. We did experim...

ea0063gp162 | Cushing's | ECE2019

Pharmacokinetics of osilodrostat following single and multiple doses of osilodrostat in healthy subjects and patients with Cushing’s disease

Han Kevin , Tauchmanova Libuse , Atkinson Susan , Darstein Christelle , Zhang Xinrui , Combes Francois Pierre , Pedroncelli Alberto M

Introduction: Osilodrostat is a potent oral 11β-hydroxylase inhibitor currently in Phase III clinical development for the treatment of Cushing’s syndrome (CS). The key pharmacokinetic (PK) properties, drug–drug interactions (DDIs), and population PK findings for osilodrostat in humans are summarized.Methods: Osilodrostat PK has been characterized in nine Phase I studies (healthy subjects and subjects with hepatic or renal impairment), two ...

ea0063gp163 | Cushing's | ECE2019

Effects of a single dose of pasireotide on glucose metabolism in patients with Cushing’s disease and predictors of diabetes mellitus developement during treatment

Barbot Mattia , Regazzo Daniela , Zilio Marialuisa , Mondin Alessandro , Lizzul Laura , Pinelli Silvia , Scaroni Carla

Introduction: Pasireotide (PAS) is an effective treatment for Cushing’s disease (CD) but its use is burdened by the high incidence of diabetes mellitus (DM). We aimed to evaluate the effect of a single subcutaneous injection of PAS on glucose metabolism in CD patients, to identify factors predicting rapid deterioration of glycaemic control.Methods: 14 patients [(f/m=12/2, mean age 43±11.3 years, follow-up 17 months (2-63)] with CD treated with ...

ea0063gp164 | Cushing's | ECE2019

Assessment of bone marrow fat by single-voxel vertebral magnetic resonance spectroscopy in cushing’s syndrome with or without vertebral fractures

Ferrau Francesco , Giovinazzo Salvatore , Tessitore Agostino , Messina Erika , Vinci Sergio , Mazziotti Gherardo , Lania Andrea , Longo Marcello , Granata Francesca , Cannavo Salvatore

Chronic hypercortisolism is associated with dramatic increase in fragility fractures. The evaluation of skeletal fragility in Cushing’s syndrome (CS) is a clinical challenge, since fractures may occur even in presence of normal bone mineral density (BMD). Recently, measurement of bone marrow fat (BMF) by vertebral magnetic resonance spectroscopy (MRS) was proposed as alternative tool for evaluating skeletal fragility in primary and secondary osteoporosis. Noteworthy, rece...